哮喘
医学
免疫系统
前列腺素
前列腺素E2受体
受体
免疫学
哮喘的病理生理学
肺
生物信息学
内科学
兴奋剂
生物
作者
Dominik Cebulla,Chiel van Geffen,Saeed Kolahian
标识
DOI:10.1016/j.pharmthera.2022.108313
摘要
Asthma is the most common airway chronic disease with treatments aimed mainly to control the symptoms. Adrenergic receptor agonists, corticosteroids and anti-leukotrienes have been used for decades, and the development of more targeted asthma treatments, known as biological therapies, were only recently established. However, due to the complexity of asthma and the limited efficacy as well as the side effects of available treatments, there is an urgent need for a new generation of asthma therapies. The anti-inflammatory and bronchodilatory effects of prostaglandin E2 in asthma are promising, yet complicated by undesirable side effects, such as cough and airway irritation. In this review, we summarize the most important literature on the role of all four E prostanoid (EP) receptors on the lung's immune and structural cells to further dissect the relevance of EP2/EP4 receptors as potential targets for future asthma therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI